APR 23, 2018 8:00 AM PDT

UFH monitoring focusing on use of anti-Xa for critically ill and general patient management

Sponsored by: Diagnostica Stago, Inc.
Speaker

Abstract

Despite the development of new anticoagulants, unfractionated heparin (UFH) continues to be a primary choice for intravenous anticoagulant therapy because of its titratability, short half-life, ability to use in patients with renal failure, and acute reversibility. UFH continues to be the mainstay of parenteral anticoagulation especially in critically ill patients and to maintain anticoagulation during mechanical cardiopulmonary support.  As with all intravenous anticoagulants, monitoring is required for its use. In critically ill patients, UFH can be monitored by multiple tests that include the activated partial thromboplastin time (aPTT), heparin activity measured by antifactor Xa (anti-Xa), or activated clotting time (ACT). Although the aPTT and the ACT are frequently used for monitoring, there are multiple limitations. Anti-Xa heparin monitoring represents an important alternative, and I routinely used anti-Xa monitoring as our standard of measurement in my previous institution. However, aPTT is the standard for monitoring in my current institution.  Despite this, I frequently use anti-Xa monitoring as an important guide to therapy especially in critically ill, complex patients especially during ECMO and mechanical cardiopulmonary support. Anti-Xa monitoring is a more direct measure of UFH activity than the aPTT, demonstrates less variability and is most helpful when conflicting values occur during aPTT monitoring.  In this presentation, I will review UFH monitoring focusing on the use of the anti-Xa for critically ill and general patient management.

Learning Objectives

  • Summarize different methods for heparin monitoring in the ICU and hospital
  • Describe limitations and benefits of different testing focusing on anti-Xa monitoring
  • Discuss the role of anti-Xa monitoring and clinical applications in critically ill patients

 

 P.A.C.E. ® Credits are no longer available for this webinar.


Show Resources
You May Also Like
AUG 10, 2022 10:00 AM PDT
AUG 10, 2022 10:00 AM PDT
Date: August 10, 2022 Time: 10:00am PDT, 1:00pm EDT The global pandemic has increased focus and scrutiny on molecular diagnostic assay development, resulting in a need for assays that provid...
APR 28, 2022 8:00 AM PDT
APR 28, 2022 8:00 AM PDT
Date: April 28, 2022 Time: 8:00am (PDT), 11:00am (EDT), 5:00pm (CEST) Human pluripotent stem cells (PSCs) and their derivatives hold great potentials in...
MAR 23, 2022 11:00 AM PDT
MAR 23, 2022 11:00 AM PDT
Date: March 23, 2021 Time: 11:00am (PDT), 2:00pm (EDT), 8:00pm (CEDT) In this presentation, Dr. Middleton will review the development and deployment of large-scale saliva-based COVID-19 test...
MAY 17, 2022 9:00 AM PDT
MAY 17, 2022 9:00 AM PDT
Date: May 17, 2022 Time: 9:00am (PDT), 12:00pm (EDT), 8:00pm (CEST) Gene therapeutics have great potential to treat many severe diseases in an unprecedented, targeted manner. The biopharmace...
JUN 28, 2022 7:00 AM PDT
JUN 28, 2022 7:00 AM PDT
Date: June 28, 2022 Time: 3:00pm (BST), 4:00pm (CET), 9:00am (CST), 7am (PST) Light-sheet microscopy is an extremely versatile imaging technique with a vast range of implementations that are...
JUN 29, 2022 8:00 AM PDT
JUN 29, 2022 8:00 AM PDT
Date: June 29, 2022 Time: 8:00am (PST), 11:00am (EST), 5:00pm (CEST) As of May 2022, there have been more than 500 million confirmed cases of COVID-19, including numerous variants. Additiona...
APR 23, 2018 8:00 AM PDT

UFH monitoring focusing on use of anti-Xa for critically ill and general patient management

Sponsored by: Diagnostica Stago, Inc.


Show Resources
Loading Comments...
Show Resources